Skip to main content

Table 1 Baseline characteristics of patients with and without end-digit preference. Data show percentages or mean values (95% confidence intervals)

From: Assessing the reliability of self-reported weight for the management of heart failure: application of fraud detection methods to a randomised trial of telemonitoring

  End-digit preference (n = 105) No end-digit preference (n = 535)
Mean age in years 60.1 (56.3 to 64.0) 64.0 (62.6 to 65.3)
Male 68.6 (55.1 to 83.0) 55.2 (50.7 to 59.6)
New York Heart Association class
 I 2.6 (0 to 8.3) 4.0 (2.3 to 5.8)
 II 43.6 (30.1 to 56.9) 35.5 (31.0 to 40.2)
 III 45.2 (30.8 to 59.8) 52.2 (47.4 to 56.5)
 IV 8.6 (0.6 to 17.6) 8.4 (5.8 to 11.2)
Race
 White 54.2 (39.4 to 67.6) 58.4 (54.2 to 62.4)
 Black 18.5 (6.0 to 32.1) 36.7 (32.5 to 41.1)
 Other 27.3 (18.1 to 37.6) 4.9 (3.0 to 7.2)
Hispanic or Latino ethnic group 0 (0 to 3.6) 3.0 (1.6 to 4.7)
LVEF < 40% 75.7 (62.4 to 88.5) 65.8 (61.2 to 70.3)
Chronic kidney disease 59.9 (44.4 to 74.2) 56.8 (52.3 to 61.5)
COPD 19.6 (8.6 to 31.3) 20.9 (17.3 to 24.8)
Diabetes mellitus 52.8 (38.9 to 67.9) 52.2 (47.4 to 56.5)
Hypertension 63.4 (50.6 to 76.8) 77.0 (73.4 to 81.1)
Coronary artery disease 55.1 (41.4 to 69.3) 60.1 (55.6 to 64.5)
Mean blood pressure
 Systolic 122.2 (115.3 to 129.0) 121.4 (119.1 to 123.8)
 Diastolic 69.7 (65.8 to 73.7) 70.2 (69.1 to 71.5)
Mean serum potassium 4.0 (3.9 to 4.2) 4.1 (4.1 to 4.2)
Mean blood urea nitrogen 31.9 (26.4 to 38.2) 28.1 (26.4 to 29.9)
Mean serum creatinine 1.6 (1.4 to 1.9) 1.5 (1.4 to 1.6)
Mean weight in lbs. 165.6 (142.9 to 187.1) 172.4 (165.8 to 179.4)
Medications
 ACE inhibitor or ARB 73.5 (59.3 to 87.5) 66.1 (61.7 to 70.6)
 Aldosterone-receptor antagonist 41.6 (29.6 to 55.2) 31.2 (27.1 to 35.5)
 Beta blocker 87.0 (76.2 to 96.7) 82.3 (78.5 to 85.7)
 Digoxin 30.2 (17.1 to 42.3) 24.5 (20.3 to 29.0)
 Loop diuretic 82.5 (71.4 to 93.9) 80.1 (76.2 to 83.6)
Graduated high school 82.0 (70.0 to 94.4) 75.6 (71.5 to 79.6)
Household income < $10,000 pa 23.6 (9.9 to 37.8) 22.4 (18.1 to 26.8)